- Home
- BTGO vs FTH Comparison
BTGO vs FTH Comparison
Compare BTGO & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTGO | FTH |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 806.4M | 835.7M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BTGO | FTH |
|---|---|---|
| Price | $5.27 | $18.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 15 |
| Target Price | $10.38 | ★ $55.38 |
| AVG Volume (30 Days) | ★ 862.6K | 345.2K |
| Earning Date | 11-09-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.67 | N/A |
| Revenue Next Year | $25.14 | N/A |
| P/E Ratio | $10.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.65 | $16.57 |
| 52 Week High | $15.30 | $42.14 |
Technical Indicators
Market Signals| Indicator | BTGO | FTH |
|---|---|---|
| Relative Strength Index (RSI) | 34.04 | 33.59 |
| Support Level | $4.70 | N/A |
| Resistance Level | $5.56 | $21.97 |
| Average True Range (ATR) | 0.44 | 2.11 |
| MACD | -0.07 | 0.14 |
| Stochastic Oscillator | 7.38 | 22.99 |
Price Performance
Historical ComparisonAbout BTGO BitGo Holdings Inc. Class A Common Stock
BitGo Holdings Inc provides various offerings to its clients including multi-signature blockchain wallet solutions allowing for secure storage, trade settlement, staking solutions, and lending of digital assets. The Company also provides professional services to develop smart contracts. Its clients range from crypto-native companies that use its self-custody wallet technology to traditional financial services firms that leverage its licensed custody, staking and trading capabilities within their own products and services.
About FTH Faeth Therapeutics Inc. Common Stock
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.